Mergers & AcquisitionsMedium•10 November 2026•
1 min read
AstraZeneca Acquires Omniose to Strengthen Infectious Disease Portfolio
Key Facts
1Omniose announced its acquisition by AstraZeneca following a three-year exclusive research collaboration.
2Omniose will become a wholly owned subsidiary of AstraZeneca within its Infectious Disease Unit.
Omniose announced its acquisition by AstraZeneca following a three-year exclusive research collaboration. Business Wire reported that Omniose will become a wholly owned subsidiary of AstraZeneca within its Infectious Disease Unit.
The acquisition integrates Omniose's proprietary bioconjugation platform to complement AstraZeneca's existing capabilities in infectious disease treatments. AZN closed at $189.39 on November 9, 2026, with the stock trading between a low of $187.21 and a high of $190.17 during that session.